オファコルカプセル 50 mg
に関する資料

第 2 部：CTD の概要（サマリー）

2.7.　臨床概要

2.7.5　参考文献

本資料に記載された情報に係る権利及び内容の責任は、株式会社レクメドに帰属するものであります。当該情報を適正使用以外の営利目的に本資料を利用することはできません。

株式会社レクメド

2.7.5 参考文献

Ahlberg, J., Angelin, B. & Einarsson, K., 1981. *Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.,* : J Lipid Res 22(3): 410-22.

Ahmad, O. et al., 2019. *Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets,* : J Endocr Soc 3(2): 397-402.

Akobeng, A. K. et al., 1999. *An inborn error of bile acid synthesis (3beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency) presenting as malabsorption leading to rickets.,* : Arch Dis Child 80(5): 463-5.

Al-Hussaini, A. A. et al., 2017. *Bile Acid Synthesis Disorders in Arabs: A 10-year Screening Study,* : J Pediatr Gastroenterol Nutr 65(6): 613-20.

Allergan USA, Inc, 2022. *KYBELLA(deoxycholic acid)injection: Highlights of prescribing information,* USA: Allergan USA, Inc.

Almé, B., Bremmelgaard, A., Sjövall, J. & Thomassen, P., 1977. *Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatorgaphy-mass spectrometry.,* : J Lipid Res 18(3): 339-62.

Angelin, B., Björkhem, I. & Einarsson, K., 1978. *Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size.,* : J Lipid Res 19(5): 527-37.

Angelin, B., Björkhem, I., Einarsson, K. & Ewerth, S., 1982. *Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum.,* : J Clin Invest 70(4): 724-31.

Balistreri, W. F., 1991. *Fetal and neonatal bile acid synthesis and metabolism-clinical implications.,* : J Inherit Metab Dis 14(4): 459-77.

Balistreri, W. F., 1995. *Inborn errors of bile acid biosynthesis: Clinical and therapeutic aspects.,* : Bile Acids in Gastroenterology: Basic and Clinical Advances. A. F. Hofmann, G. Paumgartner and A. Stiehl. London, Kluwer Academic Publishers: 333-53.

Balistreri, W. F., 1999. *Inborn errors of bile acid biosynthesis and transport. Novel forms of metabolic liver disease.,* : Gastroenterol Clin North Am 28(1): 145-72, vii.

Barth, A., Rost, M., Kindt, A. & Peiker, G., 2005. *Serum bile acid profile in women during pregnancy and childbed.,* : Exp Clin Endocrinol Diabetes 113(7): 372-5.

Bernstein, H. et al., 2005. *Bile acids as carcinogens in human gastrointestinal cancers.,* : Mutat Res 589(1): 47-65.

Besançon, F., Marche, C. & Parrot, J., 1970. *Experimental lithiasis due to excess cholic acid in mice.,* : Biol Gastroenterol (Paris) 2: 147-60.

Bossi, G. et al., 2017. *Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the HSD3B7 gene,* : Pediatr Rep 9(3): 7266.

Bove, K. E., Heubi, J. E., Balistreri, W. F. & Setchell, K. D. R., 2004. *Bile acid synthetic defects and liver disease: a comprehensive review.,* : Pediatr Dev Pathol 7(4): 315-34.

Burke, C. W., Lewis, B., Panveliwalla, D. & Tabaqchali, S., 1971. *The binding of cholic acid and its taurine conjugate to serum proteins.,* : Clin Chim Acta 32(2): 207-14.

Cheng, J. B. et al., 2003. *Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease.,* : J Clin Endocrinol Metab 88(4): 1833-41.

Clayton, P. T., 1991. *Inborn errors of bile acid metabolism.,* : J Inherit Metab Dis 14(4): 478-96.

Clayton, P. T., Casteels, M., Mieli-Vergani, G. & Lawson, A. M., 1995. *Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis?,* : Pediatr Res 37(4 Pt 1): 424-31.

Clayton, P. T. et al., 1987. *Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids.,* : J Clin Invest 79(4): 1031-8.

Clayton, P. T. et al., 1996. *(delta)4-3-Oxosteroid 5(beta)-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.,* : Gut 38: 623-8.

Clayton, P. T. et al., 2002. *Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis,* : J Inherit Metab Dis 25(6): 501-13.

Courillon, F. et al., 1998. *Serum C24 bile acids in the developing human fetus.,* : Biol Neonate 73(2): 76-88.

Daugherty, C. C., Setchell, K. D., Heubi, J. E. & Balistreri, W. F., 1993. *Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency).,* : Hepatology 18(5): 1096-101.

Dr. Falk Pharma UK Ltd, 2005. *Ursofalk Capsules (Ursodeoxycholic Acid 250 mg) - Summary of Product Characteristics.,* United Kingdom: .

Einarsson, K. & Grundy, S. M., 1980. *Effects of feeding cholic acid and chenodeoxycholic acid on cholesterol absorption and hepatic secretion of biliary lipids in man.,* : J Lipid Res 21(1): 23-34.

Everson, G. T., 1987. *Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry.,* : J Lipid Res 28(3): 238-52.

Fischler, B. et al., 2007. *Cholestatic liver disease in adults may be due to an inherited defect in bile acid biosynthesis.,* : J Intern Med 262(2): 254-62.

Forsyth, J. S., Ross, P. E. & Bouchier, I. A., 1983. *Bile salts in breast milk.,* : Eur J Pediatr 140(2): 126-7.

Gilmore, I. T. & Thompson, R. P., 1980. *Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease.,* : Gut 21(2): 123-7.

Gonzales, E., 2006. *Déficits héréditaires de synthèse des acides biliaires primaires: effets à long terme d'un traitement par l'acide cholique.,* : Faculté de Médécine Pierre et Marie Curie. Paris, Université Pierre et Marie Curie. MD: 82.

Gonzales, E. et al., 2004. *SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect.,* : J Hepatol 40(4): 716-8.

Gonzales, E. et al., 2009. *Oral Cholic acid for hereditary defects of primary bile acid synthesis: a safe and efficective long-term therapy.,* : Gastroenterology 137: 1310-20.

Gonzales, E. et al., 2018. *Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood,* : Orphanet J Rare Dis 13(1): 190.

Güldütuna, S. et al., 1993. *Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.,* : Eur J ClinPharmacol 45(3): 221-5.

Heubi, J. E., Balistreri, W. F. & Suchy, F. J., 1982. *Bile salt metabolism in the first year of life.,* : J Lab Clin Med 100(1): 127-36.

Heubi, J. E., Bove, K. E. & Setchell, K. D. R., 2017. *Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders,* : J Pediatr Gastroenterol Nutr 65(3): 321-26.

Heubi, J. E. & Setchell, K. D. R., 2020. *Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis,* : J Pediatr Gastroenterol Nutr 70(4): 423-29.

Heubi, J. E., Setchell, K. D. R. & Bove, K. E., 2007. *Inborn errors of bile acid metabolism.,* : Semin Liver Dis 27(3): 282-94.

Horslen, S. P., Lawson, A. M., Malone, M. & Clayton, P. T., 1992. *3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology.,* : J Inherit Metab Dis 15(1): 38-46.

Houten, S. M., Watanabe, M. & Auwerx, J., 2006. *Endocrine functions of bile acids.,* : Embo J 25(7): 1419-25.

Hulzebos, C. V. et al., 2001. *Measurement of parameters of cholic acid kinetics in plasma using a microscale stable isotope dilution technique: application to rodents and humans.,* : J Lipid Res 42(11): 1923-9.

Ichimiya, H. et al., 1991. *Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment.,* : J Lipid Res 32(5): 829-41.

Ichimiya, H. et al., 1990. *Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid.,* : Arch Dis Child 65(10): 1121-4.

Jacquemin, et al., 2000. *Long-term effects of bile acid therapy in children with defects of primary bile acid synthesis: 3 beta-hydroxy-C27-steroid-dehydrogenase/isomerase and delta-4-3-oxosteroid 5 beta-reductase deficiencies.,* : Biology of Bile Acids in Health and Disease. G. P. van Berge Henegouwen, D. Keppler, U. Leuschner, G. Paumgartner and A. Stiehl. Dordrecht, Boston, London, Kluwer Academic Publishers: 278-82.

Jacquemin, E. et al., 1994. *A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency.,* : J Pediatr 125(3): 379-84.

Kaye, M. D. et al., 1973. *Factors Affecting Plasma Clearance of [14C] Cholic Acid in Patients with Cirrhosis.,* : Clinical Science and Molecular Medicine 45: 147-61.

Kimura, A. et al., 1998. *Diagnosis of the first Japanese patient with 3-oxo-delta4-steroid 5beta-reductase deficiency by use of immunoblot analysis.,* : Eur J Pediatr 157(5): 386-90.

Kimura, A., Nittono, H., Takei, H. & Kurosawa, T., 2000. *Abnormally low ratio of cholic acid to chenodeoxycholic acid due to a deficiency of 3-oxo-delta4-steroid 5beta-reductase.,* : Pediatr Int 42(5): 594.

Kobayashi, M. et al., 2000. *3beta-hydroxy-delta5-C27-steroid dehydrogenase/isomerase deficiency in a 23-year-old woman.,* : Pediatr Int 42(6): 685-8.

Kondo, K. H. et al., 1994. *Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme.,* : Eur J Biochem 219(1-2): 357-63.

Koopman, B. J. et al., 1988b. *Determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates by means of stable isotope dilution technique, making use of deuterated cholic acid and chenodeoxycholic acid.,* : Clin Chim Acta 175(2): 143-55.

Koopman, B. J. et al., 1988a. *Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands,* : J Inherit Metab Dis 11(1): 56-75.

Lemonde, H. A. et al., 2003. *Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.,* : Gut 52(10): 1494-9.

Mandia, D. et al., 2019. *Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults,* : J Neurol 266(8): 2043-50.

Miller, N. E. & Nestel, P. J., 1973. *Altered bile acid metabolism during teratment with phenobarbitone.,* : Clin Sci Mol Med 45(2): 257-62.

Murai, T. et al., 2013. *Determination of 3β-hydroxy-Δ5-bile acids and related compounds in biological fluids of patients with cholestasis by liquid chromatography-tandem mass spectrometry,* : J Chromatogr B Analyt Technol Biomed Life Sci 923-924: 120-7.

Murray, K. F. & Kowdley, K. V., 2001. *Neonatal hemochromatosis.,* : Pediatrics 108(4): 960-4.

Muto, A. et al., 2012. *Detection of Δ4-3-oxo-steroid 5β-reductase deficiency by LC-ESI-MS/MS measurement of urinary bile acids,* : J Chromatogr B Analyt Technol Biomed Life Sci 900: 24-31.

Nakagawa, M. & Setchell, K. D., 1990. *Bile acid metabolism in early life: studies of amniotic fluid.,* : J Lipid Res 31(6): 1089-98.

Nittono, H. et al., 2010. *3β-hydroxy-Δ^5-C$_{27}$-steroid dehydrogenase/isomerase deficiency in a patient who underwent oral bile acid therapy for 10 years and delivered two healthy infants,* : Pediatr Int 52(4): e192-5.

Palermo, M. et al., 2008. *Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism.,* : Steroids 73(4): 417-23.

Perwaiz, S. et al., 2001. *Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry.,* : J Lipid Res 42(1): 114-9.

Pierre, G. et al., 2008. *Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy,* : J Inherit Metab Dis 31 Suppl 2: S241-5.

Potin, et al., 2001. *Evaluation du traitement des déficits de synthèse des acides biliaires primaires par l'acide cholique et/ou l'acide ursodésoxycholique dans le cadre d'un essai clinique en pédiatrie.,* : Journal de Pharmacie Clinique 20: 193-6.

Riello, L. et al., 2010. *Titration of bile acid supplements in 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase/isomerase deficiency.,* : J pediatr Gastroenterol Nutr 50(6): 655-60.

Rinawi, F. et al., 2015. *Fat malabsorption due to bile acid synthesis defect,* : Isr Med Assoc J 17(3):190-2.

Roda, A. et al., 1982. *Quantitative aspects of the interaction of bile acids with human serum albumin,* : J Lipid Res 23(3): 490-5.

Sato, K. et al., 2020. *Changes in conjugated urinary bile acids across age groups,* : Steroids 164:108730.

Setchell, K. D. R., et al., 1990. *Chronic hepatitis in 10year-old due to an inborn error in bile acid synthesis-diagnosis and treatment with oral bile acid.,* : Gastroenterology 98(5): A631 (abstr.).

Setchell, K. D. R., et al., 1991. *Oral bile acid therapy in the treatment of inborn errors in bile acid synthesis associated with liver disease.,* : Bile acids as therapeutic agents. From basic science to dinical practice. G. Paumgartner, A. Stiehl and W. Gerok. Boston, KIuwer Academic: 367-73.

Setchell, K. D., 2006. *Defects in bile acid biosynthesis--diagnosis and treatment.,* : J Pediatr Gastroenterol Nutr 43 Suppl 1: S17-22.

Setchell, K. D. R., 2004. *Defects in bile acid synthesis - specific and treatable causes of metabolic liver disease.,* : Bile Acid Biology and Its Therapeutic Implications: Proceedings of the Falk Symposium 141 (XVIII International Bile Acid Meeting) Held in Stockholm, Sweden, June 18-19 2004. G. Paumgartner, D. Keppler, U. Leuschner and A. Stiehl, Springer: 3-16.

Setchell, K. D. et al., 1998. *Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease,* : J Clin Invest 102(9): 1690-703.

Setchell, K. D. et al., 1988. *Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis.,* : J Clin Invest 82(6): 2148-57.

Shneider, B. L. et al., 1994. *Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis.,* : J Pediatr 124(2): 234-8.

Siafakas, C. G., Jonas, M. M. & Perez-Atayde, A. R., 1997. *Abnormal bile acid metabolism and neonatal hemochromatosis: a subset with poor prognosis,* : J Pediatr Gastroenterol Nutr 25(3): 321-6.

sigma-tau Arzneimittel GmbH, 2008. *Chenofalk (Chenodeoxycholic Acid 250 mg) - Summary of Product Characteristics.,* Germany: .

Stellaard, F., Paumgartner, G., van Berge Henegouwen, G. P. & van der Werf, S. D., 1986. *Determination of deoxycholic acid pool size and input rate using [24-13C]deoxycholic acid and serum sampling,* : J Lipid Res 27(11): 1222-5.

Stellaard, F., Sackmann, M., Sauerbruch, T. & Paumgartner, G., 1984. *Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids.,* : J Lipid Res 25(12): 1313-9.

Stiehl, A., Raedsch, R. & Rudolph, G., 1990. *Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids,* : Gastroenterology 98(2): 424-8.

Subramaniam, P. et al., 2010. *Variable clinical spectrum of the most common inborn error of bile acid metabolism-3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency.,* : J Pediatr Gastroenterol Nutr 50(1): 61-6.

Tauber, G. et al., 1996. *Feedback regulation of bile acid synthesis measured by stable isotope kinetics in humans.,* : Eur J Gastroenterol Hepatol 8(1): 23-31.

Tepperman, J., Caldwell, F. T. & Tepperman, H. M., 1964. *Induction Of Gallstones In Mice By Feeding A Cholesterol-Cholic Acid Containing Diet.,* : Am J Physiol 206: 628-34.

Toouli, J., Jablonski, P. & Watts, J. M., 1975. *Gallstone dissolution in man using cholic acid and lecithin.,* : Lancet 2(7945): 1124-6.

Ueki, I. et al., 2008b. *SRD5B1 gene analysis needed for the accurate diagnosis of primary 3-oxo-Delta-steroid 5beta-reductase deficiency.,* : J Gastroenterol Hepatol 24(5): 776-85.

Ueki, I. et al., 2008a. *Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7alpha-hydroxylase gene,* : J Pediatr Gastroenterol Nutr 46(4):465-9.

Vanderpas, J. B. et al., 1987. *Malabsorption of liposoluble vitamins in a child with bile acid deficiency.,* : J Pediatr Gastroenterol Nutr 6(1): 33-41.

von Bahr, S. et al., 2005. *Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy,* : J Pediatr Gastroenterol Nutr 40 (4): 481-6.

Wang, D. Q. et al., 1999. *Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis.,* : Am J Physiol 276(3 Pt 1): G751-60.

Waterreus, R. J., Koopman, B. J., Wolthers, B. G. & Oosterhuis, H. J., 1987. *Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands,* : Clin Neurol Neurosurg 89(3):169-75.

Witzleben, C. L., Piccoli, D. A. & Setchell, K., 1992. *A new category of causes of intrahepatic cholestasis.,* : Pediatr Pathol 12(2): 269-74.

Woollett, L. A. et al., 2004. *Cholic acid supplementation enhances cholesterol absorption in humans.,* : Gastroenterology 126(3): 724-31.

Yamato, Y. et al., 2001. *3beta-hydroxy-delta5 -C27-steroid dehydrogenase deficiency: diagnosis and treatment,* : J Paediatr Child Health 37(5): 516-9.